scholarly journals Local use of dexamethasone in the treatment of ocular myasthenia gravis

2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Minghua Shi ◽  
Yingjia Ye ◽  
Junping Zhou ◽  
Aijiao Qin ◽  
Jing Cheng ◽  
...  
Keyword(s):  
Myasthenia Gravis ◽  
Extraocular Muscle ◽  
Direct Injection ◽  
Response To Treatment ◽  
Clinical Trial Registry ◽  
Ocular Myasthenia ◽  
Ocular Myasthenia Gravis ◽  
Before And After ◽  
Local Use

Abstract Background At present, patients with ocular myasthenia gravis (OMG) are typically treated with systemic drugs. We investigated the use of dexamethasone injected in the peribulbar region or extraocular muscle to treat patients with OMG. Methods Patients with OMG were given dexamethasone via peribulbar injection or direct injection into the main paralyzed extraocular muscles, once a week, for 4–6 weeks. The severity of diplopia, blepharoptosis, eye position, and eye movement were evaluated before and after treatment. The duration of follow-up time was ≥6 months. Results Among the 14 patients with OMG who received this treatment, mean age was 38.7 ± 29.7 years. After treatment, symptoms were relieved in 12 patients (85.7%), 1 patient (7.1%) had partial response to treatment, and 1 patient (7.1%) had no response. Two patients (14.2%) experienced symptom recurrence during the follow-up period. Conclusions Dexamethasone peribulbar or extraocular muscle injection is effective in the treatment of patients with OMG and may replace systemic drug therapy. Trial registration Chinese Clinical Trial Registry, ChiCTR2000038863, October 7, 2020.Retrospectively registered.

scholarly journals Local Use of Dexamethasone in the Treatment of Ocular Myasthenia Gravis

2020 ◽  
Author(s):  
Minghua Shi ◽  
Yingjia Ye ◽  
Junping Zhou ◽  
Aijiao Qin ◽  
Jing Cheng ◽  
...  
Keyword(s):  
Myasthenia Gravis ◽  
Extraocular Muscle ◽  
Direct Injection ◽  
Response To Treatment ◽  
Clinical Trial Registry ◽  
Ocular Myasthenia ◽  
Ocular Myasthenia Gravis ◽  
Before And After ◽  
Local Use

Abstract Background: At present, patients with ocular myasthenia gravis (OMG) are typically treated with systemic drugs. We investigated the use of dexamethasone injected in the peribulbar region or extraocular muscle to treat patients with OMG.Methods: Patients with OMG were given dexamethasone via peribulbar injection or direct injection into the main paralyzed extraocular muscles, once a week, for 4-6 weeks. The severity of diplopia, blepharoptosis, eye position, and eye movement were evaluated before and after treatment. The duration of follow-up time was ≥6 months.Results: Among the 14 patients with OMG who received this treatment, mean age was 38.7 ± 29.7 years. After treatment, symptoms were relieved in 12 patients (85.7%), 1 patient (7.1%) had partial response to treatment, and 1 patient (7.1%) had no response. Two patients (14.2%) experienced symptom recurrence during the follow-up period.Conclusions: Dexamethasone peribulbar or extraocular muscle injection is effective in the treatment of patients with OMG and may replace systemic drug therapy.Trial registration: Chinese Clinical Trial Registry, ChiCTR2000038863, October 7, 2020.Retrospectively registered.

scholarly journals Local Use of Dexamethasone in the Treatment of Ocular Myasthenia Gravis

2020 ◽  
Author(s):  
Minghua Shi ◽  
Yingjia Ye ◽  
Junping Zhou ◽  
Aijiao Qin ◽  
Jing Cheng ◽  
...  
Keyword(s):  
Myasthenia Gravis ◽  
Extraocular Muscle ◽  
Direct Injection ◽  
Response To Treatment ◽  
Ocular Myasthenia ◽  
Ocular Myasthenia Gravis ◽  
Before And After ◽  
Local Use ◽  
Symptom Recurrence

Abstract Background: At present, patients with ocular myasthenia gravis (OMG) are typically treated with systemic drugs. We investigated the use of dexamethasone injected in the peribulbar region or extraocular muscle to treat patients with OMG. Methods: Patients with OMG were given dexamethasone via peribulbar injection or direct injection into the main paralyzed extraocular muscles, once a week, for 4-6 weeks. The severity of diplopia, blepharoptosis, eye position, and eye movement were evaluated before and after treatment. The duration of follow-up time was ≥6 months. Results: Among the 14 patients with OMG who received this treatment, mean age was 38.7 ± 29.7 years. After treatment, symptoms were relieved in 12 patients (85.7%), 1 patient (7.1%) had partial response to treatment, and 1 patient (7.1%) had no response. Two patients (14.2%) experienced symptom recurrence during the follow-up period.Conclusions: Dexamethasone peribulbar or extraocular muscle injection is effective in the treatment of patients with OMG and may replace systemic drug therapy.

scholarly journals Local Use of Dexamethasone in the Treatment of Ocular Myasthenia Gravis

2020 ◽  
Author(s):  
Minghua Shi ◽  
Yingjia Ye ◽  
Junping Zhou ◽  
Aijiao Qin ◽  
Jing Cheng ◽  
...  
Keyword(s):  
Myasthenia Gravis ◽  
Extraocular Muscle ◽  
Direct Injection ◽  
Patient Treatment ◽  
Ocular Myasthenia ◽  
Ocular Myasthenia Gravis ◽  
Before And After ◽  
Local Use ◽  
Symptom Recurrence

Abstract Background At present, patients with ocular myasthenia gravis (OMG) are typically treated with systemic drugs. We investigated the use of dexamethasone injected in the peribulbar region or extraocular muscle to treat patients with OMG. Methods Patients with OMG were given dexamethasone via peribulbar injection or direct injection into the main paralyzed extraocular muscles, once a week, for 4-6 weeks. The severity of diplopia, blepharoptosis, eye position, and eye movement were evaluated before and after treatment. The duration of follow-up time was ≥6 months. Results Among the 14 patients with OMG who received this treatment, mean age was 38.7 ± 29.7 years. After treatment, symptoms had resolved in 12 patients; symptoms had improved in 1 patient; treatment had failed in 1 patient. Two of the 12 patients in whom symptoms had resolved experienced symptom recurrence during the follow-up period. Conclusions Dexamethasone peribulbar or extraocular muscle injection is effective in the treatment of patients with OMG and may replace systemic drug therapy

scholarly journals Seeking spark- ocular myasthenia gravis in a juvenile – an Indian case report

2020 ◽  
Vol 5 (7) ◽  
pp. 190-193
Author(s):  
Dr. Usha BR. ◽  
◽  
Dr. Nandhini K ◽  
Dr. Chaitra MC ◽  
◽  
...  
Keyword(s):  
Case Report ◽  
Neuromuscular Junction ◽  
Myasthenia Gravis ◽  
Autoimmune Disorder ◽  
Bilateral Ptosis ◽  
Ocular Myasthenia ◽  
Ocular Myasthenia Gravis ◽  
History Of ◽  
High Index Of Suspicion

Myasthenia gravis (MG) is a rare autoimmune disorder affecting neuromuscular junction by muscleweakness. Myasthenia gravis can be generalized or localized as ocular myasthenia gravis. Casepresentation: We report an 8-year-old boy who presented with 10 days history of drooping of botheyelids and 8 days history of diplopia. Examination revealed bilateral ptosis. A diagnosis of JuvenileOcular Myasthenia gravis was made when symptoms improved with intramuscular Edrophoniumadministration. He was commenced on oral Neostigmine at a dose of 2mg/Kg/ day,4 hourly individed doses and is on regular follow up and had a good response. Conclusion: Ocular Myastheniagravis (OMG) is a rare disease in itself. A high index of suspicion is required in a juvenile as it iseven rarer.

scholarly journals Long-Term Follow-Up of Strabismus Surgery for Patients With Ocular Myasthenia Gravis

2013 ◽  
Vol 33 (1) ◽  
pp. 40-44 ◽  
Author(s):  
Jason H. Peragallo ◽  
Federico G. Velez ◽  
Joseph L. Demer ◽  
Stacy L. Pineles
Keyword(s):  
Myasthenia Gravis ◽  
Strabismus Surgery ◽  
Ocular Myasthenia ◽  
Ocular Myasthenia Gravis ◽  
Long Term Follow Up

scholarly journals Thymectomy in ocular myasthenia gravis before generalization results in a higher remission rate

2019 ◽  
Author(s):  
Feng Li ◽  
Zhongmin Li ◽  
Yanli Chen ◽  
Gero Bauer ◽  
Deniz Uluk ◽  
...  
Keyword(s):  
Myasthenia Gravis ◽  
Remission Rate ◽  
Post Intervention ◽  
Data Set ◽  
Ocular Myasthenia ◽  
Ocular Symptoms ◽  
Ocular Myasthenia Gravis ◽  
Before And After ◽  
Robotic Thymectomy ◽  
Lost To Follow Up

Abstract OBJECTIVES This study aimed to compare the outcomes of patients with ocular myasthenia gravis (OMG) who underwent thymectomy before generalization with the outcomes of those who underwent thymectomy after generalization. METHODS We retrospectively reviewed patients who underwent robotic thymectomy for myasthenia gravis between January 2003 and February 2018. Patients who presented with purely ocular symptoms at myasthenia gravis onset were eligible for inclusion. Exclusion criteria were patients who were lost to follow-up and patients who underwent re-thymectomy. Patients with OMG who developed generalization before thymectomy were categorized into gOMG group and those who did not were categorized into OMG group. The primary outcome was complete stable remission according to the Myasthenia Gravis Foundation of America Post-Intervention Status (MGFA-PIS). RESULTS One hundred and sixty-five (66 males and 99 females) out of 596 patients with myasthenia gravis were eligible for inclusion. Of these, there were 73 and 92 patients undergoing thymectomy before and after the generalization of OMG, respectively. After propensity score matching, a data set of 130 patients (65 per group) was formed and evaluating results showed no statistical differences between the 2 groups. The estimated cumulative probabilities of complete stable remission at 5 years were 49.5% [95% confidence interval (CI) 0.345–0.611] in the OMG group and 33.4% (95% CI 0.176–0.462) in the gOMG group (P = 0.0053). Similar results were also found in patients with non-thymomatous subgroup [55 patients per group, OMG vs gOMG, 53.5% (95% CI 0.370–0.656) vs 28.9% (95% CI 0.131–0.419), P = 0.0041]. CONCLUSIONS Thymectomy in OMG before generalization might result in a higher rate of complete stable remission than thymectomy after generalization.

Response to treatment in pediatric ocular myasthenia gravis

2019 ◽  
Vol 61 (2) ◽  
pp. 226-230
Author(s):  
Lori Xu ◽  
Diana Castro ◽  
Joan S. Reisch ◽  
Susan T. Iannaccone
Keyword(s):  
Myasthenia Gravis ◽  
Response To Treatment ◽  
Ocular Myasthenia ◽  
Ocular Myasthenia Gravis
Sign in / Sign up

Export Citation Format

Share Document